Dave Weisman

Dave Weisman

@dweisman.bsky.social

Amylysis. Skeptical doesn’t mean cynical.

749 followers640 following525 posts

Dave Weisman reposted

The New Yorker
@newyorker.com

Short sleepers, who make up less than one per cent of the population, spend significantly less than eight hours snoozing without any apparent health consequences. What can these rare individuals teach us about our relationship with rest? newyorkermag.visitlink.me/WQhwQk

newyorkermag.visitlink.meWhy Some People Thrive on Four Hours of SleepShort sleepers, who make up less than one per cent of the population, spend significantly less time snoozing without any apparent health consequences.
Dave Weisman
@dweisman.bsky.social

Read this if you are into Alzheimer's disease. It will help reframe your mind.

Dylan Williams@dylwil.bsky.social

I'm starting a thread on misunderstandings about the role of APOE in Alzheimer's disease / dementia, from the POV of epidemiology / statistical genetics. I will add to this sporadically over time... #endalz #episky #medsky

Dave Weisman
@dweisman.bsky.social

The Novo GLP trial failed in AD. Beware lack of mechanism and loss for repurposed drugs. www.neurologylive.com/view/glp-1-s...

neurologylive.comGLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease | NeurologyLive - Clinical Neurology News and Neurology Expert InsightsResults from the EVOKE and EVOKE+ phase 3 studies reported that oral semaglutide did not significantly reduce clinical progression in patients with early symptomatic Alzheimer disease.
Dave Weisman
@dweisman.bsky.social

Weird case of Oxytocin helping with agitation. journals.sagepub.com/doi/10.1177/...

journals.sagepub.comIntranasal Oxytocin for Managing Agitation in a Patient of Mixed Dementia With Multiple Pathologies, Particularly With a History of Repetitive Head Injuries - Naresh Jadav, Sümeyye Kuş, James Ellison,...Background Agitation is common in persons living with dementia (major neurocognitive disorder) and worsens with disease progression. Brexpiprazole is the sole F...
Dave Weisman
@dweisman.bsky.social

This entire Sage story added nothing to patient care or to the economy. Just wasted efforts to rearrange the deck chairs. Then set all the staff adrift. www.biospace.com/business/sag...

biospace.comSage’s Search for Lifeline Ran Into Defiant Biogen CEOAfter the FDA rejection of Zurzuvae in one type of depression and the triple failure of neuro asset dalzanemdor, Sage was searching for a path forward at the end of December 2024. Biogen CEO Chris Vie...
Dave Weisman
@dweisman.bsky.social

This comes up all the time. Great idea, I hope this is implemented widely.

Dean Brenner@deanrbrenner.bsky.social

Know anyone diagnosed with Alzheimer's? So challenging for him/her & the family. @alzassociation.bsky.social just put out this great app for these folks- to connect them w/resources & to help them navigate this hard time. Please spread the word about this app. #endalz www.alz.org/news/2025/mo...

alz.orgAlzheimer’s Association Launches Free Mobile App to Support Newly Diagnosed Individuals and Care PartnersMy ALZ Journey offers early-stage individuals and their care partners personalized guidance, tools, and local resources to navigate Alzheimer's and dementia.
Dave Weisman
@dweisman.bsky.social

"Unless these journals change dramatically, we are going to stop NIH scientists from publishing there, and we're going to create our own journals... They're going to become the pre-eminent journals, because if you get NIH funding, it is anointing you as a good, legitimate scientist." -K Jr. What?

Dave Weisman
@dweisman.bsky.social

The Wash U lecanemab paper is a hard act to follow. But here’s a combo experience with a private clinic and U Wash. link.springer.com/article/10.1...

link.springer.comMonoclonal antibody administration in an academic institution and private neurological practice: a tale of two clinics - Journal of NeurologyThe emergence of monoclonal antibody (MABs) drugs since the FDA approval of lecanemab has resulted in dramatic changes in the clinical approach and management of early-stage Alzheimer’s disease (AD). ...
Dave Weisman
@dweisman.bsky.social

Things that resonated with me: IRRs can be severe and result in falls. Beware. Should we treat superficial siderosis as contra-indication? Out of 7 people with SS, 1 had symptomatic ARIA (also had 5 MH's). One patient was taken off therapy due to insurance coverage: no words.

Dave Weisman
@dweisman.bsky.social

Otherwise discontinuations were low. ARIA rates lower than trial (also APOE44 lower). 1-2% symptomatic ARIA. Looks like BBBx are ready for prime time (in the most expert hands). I still like CSF and PET.

Dave Weisman
@dweisman.bsky.social

1. Function was stable a year later on average, n-psych scores improved. 2. Door to needle (memory loss, dx, MRI, APOE, biomarker, to IV lec) time improved drastically to just over 2 months.

Dave Weisman
@dweisman.bsky.social

Amazing work. Dissociate amyloid from tau, could be huge effect.

Yakeel T. Quiroz, PhD@ytquiroz.bsky.social

It's great to see our work with doña Aliria and the APOE3 Christchurch variant featured in Nature Outlook. It was a true honor to work with doña Aliria and her family, and to help ensure her story is part of the larger narrative of resilience against Alzheimer’s 🧠 www.nature.com/articles/d41...

nature.comThe unusual genetic inheritance that could change Alzheimer’s treatmentThe genes of a Colombian woman who beat the odds might lead to a new way to tackle the disease.
Dave Weisman
@dweisman.bsky.social

Patient, "I called the guy on call last week, wow, he sounded stressed out. I said, 'hey, don't worry about me, I'll call back later.'" It is so weird and rare to have compassion flowing from patients towards doctors.